Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaFRA:BA3 -0.70%78 Return-on-Tangible-Asset is 0.79% as of Jun. 2026, which is 91% below its 10-year median of 9.27. GuruFocus rates FRA:BA3 with a GF Score™ of 78/100 and a GF Value™ of €45.15 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Azenta ranks worse than 64.83% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Azenta's annualizedNet Income for the quarter that ended in Jun. 2026 was €8.5 Mil. Azenta's average total tangible assets for the quarter that ended in Jun. 2026 was €1,084.2 Mil. Therefore, Azenta's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 0.79%.
The historical rank and industry rank for Azenta's Return-on-Tangible-Asset or its related term are showing as below:
FRA:BA3'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -14.12 Med: 9.27 Max: 101.86
Current: -9.85
During the past 13 years, Azenta's highest Return-on-Tangible-Asset was 101.86%. The lowest was -14.12%. And the median was 9.27%.
FRA:BA3's Return-on-Tangible-Asset is ranked worse than 64.83% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs FRA:BA3: -9.85
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Azenta Return-on-Tangible-Asset Related Terms
Azenta Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Azenta's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BA3 vs KMTS, STAA, BLFS: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Azenta's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Azenta's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.79% mean?
Azenta (FRA:BA3) has a Return-on-Tangible-Asset of 0.79% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Azenta and its competitors. This is 91% below median its historical median of 9.27. According to the industry distribution chart, Azenta ranks #553 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 64.8%.
Is Azenta's Return-on-Tangible-Asset too high?
Azenta's current Return-on-Tangible-Asset of 0.79% is 91% below median its 10-year median of 9.27. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. Azenta's value of 0.79% is 11.2% below this industry median. Based on the distribution chart, Azenta ranks #553 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's Return-on-Tangible-Asset compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #553 out of 853 companies for Return-on-Tangible-Asset. This places Azenta in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.89. Azenta's value of 0.79% is 11.2% below this benchmark. While the company's 10-year median is 9.27 vs. the industry median of 0.89, Azenta has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Azenta's current Return-on-Tangible-Asset of 0.79% is 11.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Azenta and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current Return-on-Tangible-Asset is 0.79%, which is 91% below median its own 10-year median of 9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (FRA:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.15, compared to a current price of €28.40 — trading 37.1% below its estimated fair value. The current Return-on-Tangible-Asset is 0.79%, which is 91% below median its 10-year median of 9.27 and 11.2% below the Medical Devices & Instruments industry median of 0.89. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Azenta (FRA:BA3), the current Return-on-Tangible-Asset is 0.79% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (FRA:BA3) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of €28.40 is trading 37.1% below its estimated GF Value™ of €45.15.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for FRA:BA3:
Return-on-Tangible-Asset: 0.79% (91% below median its 10-year median of 9.27)
GF Value™: €45.15 vs. price of €28.40 (37.1% below fair value)
Industry Position: 11.2% below the Medical Devices & Instruments median (#553 of 853)
No single metric tells the full story. See the FRA:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for FRA:BA3
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BA3 has been successfully added to your 
